BioTech IP Review

Patent Number: US 12,442,002 B2
Filing Date: December 19, 2024
Patent Issue Date: October 14, 2025
Assignee: Arrowhead Pharmaceuticals, Inc. (Pasadena, CA, USA)
Publication Family: WO/2025/137390 (published June 26, 2025)

---

What This Patent Covers

This U.S. patent covers RNA interference (RNAi) agents — including chemically modified small interfering RNAs (siRNAs) — that selectively reduce expression of the activin receptor‑like kinase 7 (ALK7) gene, along with compositions and therapeutic methods using those agents:

RNAi Molecules:
The invention discloses double‑stranded RNAi agents designed to bind specifically to the ALK7 mRNA, triggering RNAi‑mediated degradation and silencing ALK7 gene expression in target tissues.

Pharmaceutical Compositions:
The patent claims pharmaceutical compositions containing these RNAi agents, optionally conjugated to targeting ligands or pharmacokinetic modulators to facilitate delivery (e.g., to adipose tissue).

Methods of Use:
It includes methods of administering the RNAi agents to subjects for treating or preventing conditions where reducing ALK7 expression is beneficial. Because ALK7 is implicated in metabolic processes, lowering its activity can potentially treat or ameliorate metabolic diseases associated with obesity, diabetes, insulin resistance, and related disorders.

Mechanistic Insight:
ALK7 (also called ACVR1C) encodes a receptor in the TGF‑β superfamily that affects adipocyte function and metabolism; modulating its activity has shown preclinical promise for influencing fat accumulation and glucose homeostasis.

---

Why This Patent Is Important

1) Aligns with Large Patient Populations & Markets:
Metabolic diseases such as obesity and type‑2 diabetes affect hundreds of millions worldwide and represent some of the largest therapeutic markets globally. A successful RNAi therapy targeting ALK7 could potentially tap into these multi‑billion‑dollar markets.

2) Expands Arrowhead’s RNAi Portfolio Beyond FCS:
Arrowhead’s first FDA‑approved drug, REDEMPLO (plozasiran), targets APOC3 and marks the company’s transition to a marketed RNAi therapy with estimated future sales in the billion‑dollar range. This ALK7 patent positions Arrowhead to build out its metabolic disease franchise using the same TRiM™ RNAi platform.

3) Strengthens Platform IP:
This patent adds to Arrowhead’s growing IP covering RNAi agents (e.g., for APOC3, CFB, C3, INHBE and others) that enhance its portfolio’s breadth and supports future product candidates against diverse targets.

4) Closer to Clinical Translation:
Related therapies (e.g., ARO‑ALK7) are already in clinical planning stages or regulatory submission, demonstrating strategic progression from IP to development candidate.